Related Experiment Video
Updated: Jan 22, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single
Giacomo Barchiesi1,2, Amelia McCartney1, Chiara Biagioni3
1Sandro Pitigliani" Department of Oncology, Ospedale Santo Stefano, Prato, Italy.
Abstract:
Overall survival (OS), disease-free survival (DFS), and distant recurrence-free interval (DRFI) were evaluated from 169 patients diagnosed with early triple negative breast cancer. Overall, 5 and 10 years OS, DFS, and DRFI were 77% and 65%; 60% and 46%; and 74% and 73%, respectively. Forty-seven patients did not receive chemotherapy. A separate analysis was performed excluding those patients. In this subgroup, 5- and 10-year OS, DFS, and DRFI were 86% and 77%; 68% and 54%, 77% both at 5 and 10 years. Prognosis is better than previously described; adjuvant chemotherapy should be offered to fit elderly patients if clinically warranted.
Related Concept Videos
Predicting Reaction Outcomes
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Cancer Survival Analysis
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Negative Regulator Molecules
Positive, Negative, and Zero Work

